Dr. Robert Davey, PhD is a currently a Professor of Microbiology at the Boston University School of Medicine. Dr. Davey received his doctorate in Microbiology and Immunology at the University of Adelaide in Australia. He continued his training as a Postdoctoral Fellow at the Howard Hughes Medical Institute and then at the Division of Hematology, both with Dr. James Cunningham at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Davey’s first academic appointment was as an Instructor in Medicine at Harvard. He then held an Assistant Professor position which he got promoted to Adjunct Associate Professor at the Department of Microbiology and Immunology at the University of Texas Medical Branch.
Dr. Davey was also a Ewing Halsell Scholar and Scientist at the Department of Virology and Immunology at the Texas Biomedical Research Institute. As a Scientist at the Texas Biomedical Research Institute, Dr. Davey’s work was focused on identification of cellular factors important for establishing infection by filovirus and bunyaviruses. His work has culminated in a deeper understanding of the entry and cell signaling pathways that are used by these viruses to penetrate the cell membrane and establish infection. His work with Ebolavirus has been published in the high-impact journals PLoS Pathogens, PNAS and a new article on host factor dependence in Science that was featured on the cover page. Dr. Davey’s group works collaboratively with a number of groups providing sophisticated molecular biology and cell biology techniques for the study of pathogenic viruses including Ebolavirus for which the lab mainly works. He has developed high throughput screening techniques for Ebolavirus. He also performs contract work testing drugs and compounds for ebolavirus infection inhibition. His team is well trained in ABSL4 procedures and have been working with Ebolavirus since 2006.
From 2015-2017, Dr. Davey held the role of Interim Chair in the Department of Virology and Immunology at the Texas Biomedical Research Institute. He is also Director of ABSL4 at the Texas Biomedical Research Institute.
- Faculty, National Emerging Infectious Disease Lab, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- Published on 6/17/2020
Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, Davey RA, Thatcher GRJ, Rong L. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jun 17. PMID: 32490678.
- Published on 3/13/2020
Pavlovich SS, Darling T, Hume AJ, Davey RA, Feng F, Mühlberger E, Kepler TB. Egyptian Rousette IFN-? Subtypes Elicit Distinct Antiviral Effects and Transcriptional Responses in Conspecific Cells. Front Immunol. 2020; 11:435. PMID: 32231668.
- Published on 2/12/2020
Yurdakul C, Avci O, Matlock A, Devaux AJ, Quintero MV, Ozbay E, Davey RA, Connor JH, Karl WC, Tian L, Ünlü MS. High-Throughput, High-Resolution Interferometric Light Microscopy of Biological Nanoparticles. ACS Nano. 2020 02 25; 14(2):2002-2013. PMID: 32003974.
- Published on 11/21/2019
Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection. PLoS Negl Trop Dis. 2019 11; 13(11):e0007890. PMID: 31751347.
- Published on 7/2/2019
Wu Y, Pons V, Noël R, Kali S, Shtanko O, Davey RA, Popoff MR, Tordo N, Gillet D, Cintrat JC, Barbier J. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses. ACS Med Chem Lett. 2019 Aug 08; 10(8):1140-1147. PMID: 31413797.
- Published on 5/17/2019
Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharm Res. 2019 May 17; 36(7):104. PMID: 31101988.
- Published on 1/30/2019
Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS, Davey RA, Madrid PB, Ekins S. Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. ACS Omega. 2019 Jan 31; 4(1):2353-2361. PMID: 30729228.
- Published on 12/13/2018
Batra J, Hultquist JF, Liu D, Shtanko O, Von Dollen J, Satkamp L, Jang GM, Luthra P, Schwarz TM, Small GI, Arnett E, Anantpadma M, Reyes A, Leung DW, Kaake R, Haas P, Schmidt CB, Schlesinger LS, LaCount DJ, Davey RA, Amarasinghe GK, Basler CF, Krogan NJ. Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication. Cell. 2018 12 13; 175(7):1917-1930.e13. PMID: 30550789.
- Published on 11/30/2018
Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, Davey RA, Rong L. Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. Viruses. 2018 11 30; 10(12). PMID: 30513600.
- Published on 11/28/2018
Lindstrom A, Anantpadma M, Baker L, Raghavendra NM, Davey R, Davisson VJ. Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H+ )-ATPase Inhibition. ChemMedChem. 2018 12 20; 13(24):2664-2676. PMID: 30335906.
View 75 more publications: View full profile at BUMC